Jpmorgan Chase & CO Cidara Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Cidara Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 451 shares of CDTX stock, worth $5,723. This represents 0.0% of its overall portfolio holdings.
Number of Shares
451
Previous 1,434
68.55%
Holding current value
$5,723
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CDTX
# of Institutions
52Shares Held
22.1MCall Options Held
2.7KPut Options Held
100-
Bvf Inc San Francisco, CA6.86MShares$87.1 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.35MShares$42.5 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.55MShares$32.4 Million0.0% of portfolio
-
Alethea Capital Management, LLC San Diego, CA1.6MShares$20.3 Million1.21% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.25MShares$15.9 Million0.0% of portfolio
About Cidara Therapeutics, Inc.
- Ticker CDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,075,696
- Market Cap $889M
- Description
- Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...